Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Deflazacort

FDA-approved product (tablet, oral), marketed as Deflazacort, Emflaza, Jaythari and 1 more.

Registered studies
24
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Deflazacort
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Duchenne muscular dystrophy
  • Muscular dystrophy
  • Qualitative or quantitative defects of dysferlin

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Glucocorticoids
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Deflazacort in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Deflazacort with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Omega-3-Based Nutraceutical Supplementation as Adjunctive Therapy in Adults With Otitis Media With Effusion: A Multicenter, Double-Blind, Randomized Placebo-Controlled Trial

    NCT07721610 · start 2025-10-01

    Registered record
    Registry ID
    NCT07721610
    Conditions
    Otits Media With Effusion
    Interventions
    Omega-3-based nutraceutical combination (Otoair Flogo); Bilastine 20 mg; Placebo Tablet or Capsule; Intranasal mometasone furoate spray; Oral deflazacort 30 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2025-10-01
    Completion
    2026-05-01
    Enrolment
    501

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOtits Media With Effusion
    InterventionOmega-3-based nutraceutical combination (Otoair Flogo); Bilastine 20 mg; Placebo Tablet or Capsule; Intranasal mometasone furoate spray +1 more
    PhasePhase 4
    Registry statusCompleted

  • The Nationwide Real-world Status of Oral Corticosteroid Use in Patients With Asthma

    NCT05750797 · start 2023-03-01

    Registered record
    Registry ID
    NCT05750797
    Conditions
    Asthma; Corticosteroid
    Interventions
    Oral corticosteroids
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2023-03-01
    Completion
    2023-12
    Enrolment
    800,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma; Corticosteroid
    InterventionOral corticosteroids
    PhaseNot recorded
    Registry statusUnknown

  • Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMD

    NCT04632940 · start 2021-03-03

    Registered record
    Registry ID
    NCT04632940
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Pamrevlumab; Placebo; Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-03-03
    Completion
    2023-12-14
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionPamrevlumab; Placebo; Corticosteroids
    PhasePhase 3
    Registry statusTerminated

  • Study of the Excretion of Orally Administered Corticosteroids for the Improval of the Detection of Said Substances in Anti-doping Controls

    NCT04791345 · start 2021-02-26

    Registered record
    Registry ID
    NCT04791345
    Conditions
    Healthy Volunteers
    Interventions
    Methylprednisone; Methylprednisone; Deflazacort; Dexamethasone; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2021-02-26
    Completion
    2022-02-26
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionMethylprednisone; Methylprednisone; Deflazacort; Dexamethasone +1 more
    PhasePhase 1
    Registry statusUnknown

  • Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)

    NCT04371666 · start 2020-08-10

    Registered record
    Registry ID
    NCT04371666
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Pamrevlumab; Placebo; Corticosteroids
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2020-08-10
    Completion
    2023-08-17
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionPamrevlumab; Placebo; Corticosteroids
    PhasePhase 3
    Registry statusTerminated

  • Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects

    NCT04543370 · start 2020-08-08

    Registered record
    Registry ID
    NCT04543370
    Conditions
    Healthy
    Interventions
    Edasalonexent 2000 mg TID; Midazolam 2 MG/ML; Deflazacort 36Mg Tab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-08-08
    Completion
    2020-10-01
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionEdasalonexent 2000 mg TID; Midazolam 2 MG/ML; Deflazacort 36Mg Tab
    PhasePhase 1
    Registry statusCompleted

  • Deflazacort Vs. Prednisolone in Acute-stage ABPA

    NCT04227483 · start 2020-01-15

    Registered record
    Registry ID
    NCT04227483
    Conditions
    Allergic Bronchopulmonary Aspergillosis
    Interventions
    Deflazacort; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2020-01-15
    Completion
    2025-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Bronchopulmonary Aspergillosis
    InterventionDeflazacort; Prednisolone
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)

    NCT03783923 · start 2019-10-31

    Registered record
    Registry ID
    NCT03783923
    Conditions
    Limb-Girdle Muscular Dystrophy
    Interventions
    Deflazacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2019-10-31
    Completion
    2021-01-01
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLimb-Girdle Muscular Dystrophy
    InterventionDeflazacort
    PhasePhase 3
    Registry statusTerminated

  • Evaluation of the Effects of Pre-operative Deflazacort on Post-operative Pain, Edema and Trismus

    NCT04365088 · start 2018-12-15

    Registered record
    Registry ID
    NCT04365088
    Conditions
    Impacted Third Molar Tooth
    Interventions
    Deflazacort 30 MG Oral Tablet; Sugar pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2018-12-15
    Completion
    2023-12-15
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImpacted Third Molar Tooth
    InterventionDeflazacort 30 MG Oral Tablet; Sugar pill
    PhasePhase 4
    Registry statusUnknown

  • A Study of Deflazacort (Emflaza®) in Participants With Duchenne Muscular Dystrophy (DMD)

    NCT03642145 · start 2018-10-31

    Registered record
    Registry ID
    NCT03642145
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Deflazacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2018-10-31
    Completion
    2021-07-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionDeflazacort
    PhasePhase 3
    Registry statusWithdrawn

  • Registry of IgA Nephropathy in Chinese Children

    NCT03015974 · start 2016-01

    Registered record
    Registry ID
    NCT03015974
    Conditions
    IgA Nephropathy; Proteinuria in Nephrotic Range; Immunosuppressive Treatment
    Interventions
    Corticosteroid; Cyclophosphamide; Mycophenolate mofetil; Dipyridamole; ACE Inhibitor or Angiotensin receptor antagonist
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-01
    Completion
    2024-12
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIgA Nephropathy; Proteinuria in Nephrotic Range; Immunosuppressive Treatment
    InterventionCorticosteroid; Cyclophosphamide; Mycophenolate mofetil; Dipyridamole +1 more
    PhaseNot recorded
    Registry statusUnknown

  • Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers

    NCT02485431 · start 2015-06

    Registered record
    Registry ID
    NCT02485431
    Conditions
    Healthy Volunteers
    Interventions
    Deflazacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06
    Completion
    2015-08
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionDeflazacort
    PhasePhase 1
    Registry statusCompleted

  • A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy

    NCT02251600 · start 2014-12

    Registered record
    Registry ID
    NCT02251600
    Conditions
    Duchenne Muscular Dystrophy
    Interventions
    Deflazacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-12
    Completion
    2015-10
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDuchenne Muscular Dystrophy
    InterventionDeflazacort
    PhasePhase 1
    Registry statusCompleted

  • A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics

    NCT02286609 · start 2014-12

    Registered record
    Registry ID
    NCT02286609
    Conditions
    Hepatic Impairment
    Interventions
    Deflazacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-12
    Completion
    2015-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Impairment
    InterventionDeflazacort
    PhasePhase 1
    Registry statusCompleted

  • A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics

    NCT02286622 · start 2014-12

    Registered record
    Registry ID
    NCT02286622
    Conditions
    Renal Impairment
    Interventions
    Deflazacort
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-12
    Completion
    2015-02
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Impairment
    InterventionDeflazacort
    PhasePhase 1
    Registry statusCompleted